Skip to main content

Advertisement

Table 1 Patient characteristics (n = 134)

From: Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients

Age Median (years) 53
  Range 10–78
Bone tumor   29 (21.6%)
 Primary site Humerus 2 (1.5%)
  Spine 6 (4.5%)
  Femur 16 (11.9%)
  Tibia 3 (2.2%)
  Others 2 (1.5%)
Soft tissue tumor   105 (78.4%)
 Primary site Head and neck 4 (3.0%)
  Shoulder girdle 3 (2.2%)
  Upper arm 3 (2.2%)
  Forearm 6 (4.5%)
  Other upper extremity 5 (3.7%)
  Chest wall 4 (3.0%)
  Buttock 6 (4.5%)
  Retroperitoneum 14 (10.4%)
  Visceral 10 (7.5%)
  Thigh 25 (18.7%)
  Leg 9 (6.7%)
  Other lower extremity 9 (6.7%)
  Others 7 (5.2%)
Histological subtype
  Leiomyosarcoma 38 (28.4%)
  Undifferentiated pleomorphic sarcoma 20 (14.9%)
  Osteosarcoma 17 (12.7%)
  Liposarcoma 9 (6.7%)
  Synovial sarcoma 7 (5.2%)
  Malignant peripheral nerve sheath tumor 7 (5.2%)
  Angiosarcoma 4 (3.0%)
  Ewing sarcoma 4 (3.0%)
  Epithelioid sarcoma 4 (3.0%)
  Rhabdomyosarcoma 3 (2.2%)
  Others 21 (15.7%)
Presentation status
  Localized 9 (6.7%)
  Metastatic or locally advanced 125 (93.3%)
Prior chemotherapy regimen
  DOX+IFO 38 (28.4%)
  DOX alone 21 (15.7%)
  IFO alone 18 (13.4%)
  IFO+VP16 12 (9.0%)
  IFO+CDBCA+VP16 11 (8.2%)
  DOX+CDDP 6 (4.5%)
  None 32 (23.9%)
Prior radiation   45 (33.6%)